41results about How to "Strong neutralizing activity" patented technology

Ultra high affinity antibodies with binding affinities in the range of 10¹⁰ M⁻¹, and even 10¹¹ M⁻¹ are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.

The present invention discloses a humanized monoclonal antibody and an application thereof, belonging to the technical field of medicine. In the invention, the humanized transformation is carried outon a rat monoclonal antibody 2A10G6, the rat monoclonal antibody 2A10G6 is expressed by baculovirus, and the humanized antibody h2A10G6 is obtained. The h2A10G6 antibody of the present invention has high affinity and neutralization activity against yellow fever virus, dengue fever and West Nile virus, and can be applied to clinical treatment and prevention of yellow fever virus, dengue virus and West Nile virus.

To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

The invention provides a Pseudorabies virus resisting monoclonal antibody, a vaccine composition containing the monoclonal antibody and an application of the vaccine composition. The monoclonal antibody has very high neutralizing potency and can be used for effectively neutralizing swine classical and variant strains of Pseudorabies virus; and the vaccine composition containing the monoclonal antibody has the characteristic of broad spectrum, application objects are free from limitations to animal species, and the preventing and treating efficacy (effect) of display of swine and canine animal experiments is excellent.

The invention aims at providing a rabies virus resistant neutralizing antibody, and particularly provides a humanized or completely humanized monoclonal antibody to meet the requirement for clinically diagnosing and/or treating rabies. A phage antibody library is prepared by adopting a phage antibody library technology and taking 32 parts of high-potency healthy human peripheral blood inoculated with rabies vaccines as a raw material; 7 ELISA positive antibodies are obtained through three rounds of screening from the phage antibody library; and furthermore, the neutralizing activity of the 7 ELISA positive antibodies is measured through an RFFIT method, wherein four ELISA positive antibodies, namely R5, R7, R8 and R9, have higher neutralizing activity in all. The rabies virus resistant neutralizing antibody with high affinity, which is provided by the invention, can be used for substituting ERIG and HRIG to carry out active and/or passive immune therapy on rabies virus seriously-exposed persons.

The invention discloses specific Zika virus neutralizing antibodies and application thereof, and belongs to the technical field of medicine. Zika E protein expressed by colibacillus serves as an antigen, through fluorescence-activated cell sorting, memory B cells capable of being specifically bound with the Zika E protein are screened in PBMCs of a Zika patient in the rehabilitation stage, the screened single B cells are subjected to a RT-PCR, the sequence and segments of the variable region of the antibody are obtained, and the variable region and the constant region are connected in an expression vector. After mammalian cell expression and purification, a series of function detection is conducted, such as the binding force of the ZIKE-E protein, the in-vitro neutralizing effect and the in-vivo protection capacity, and the three human monoclonal antibodies capable of completely protecting Zika virus infection are obtained.

The present invention relates to isolated IgA antibodies, or fragments thereof, which have variable domains derived from an antibody that specifically binds to a CD4-induced (CD4i) epitope. In particular, the isolated IgA antibodies display enhanced neutralization activity relative to their IgG, non-chimeric counterparts. The invention also provides methods for therapy with the isolated IgA antibodies for the treatment of a subject having a viral infection or having an increased risk of a viral infection.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. In particular, the invention relates to a monoclonal antibody against novel coronaviruses, and a composition (e.g., diagnostic and therapeutic agents) comprising the antibody. In addition, the invention also relates to an application of the antibody. The antibody can be used for diagnosing, preventing and/or treating infection of the novel coronaviruses and/or diseases caused by the infection (e.g., novel coronavirus pneumonia).

The invention discloses a hydroxy-aluminum montmorillonite chewable tablet as well as a preparation method and application thereof. The hydroxy-aluminum montmorillonite chewable tablet disclosed by the invention is characterized in that hydroxy-aluminum montmorillonite is taken as an effective component of a medicament; the mass percentage of the hydroxy-aluminum montmorillonite in the chewable tablet is 50 to 80 percent; proper pharmaceutic adjuvants are added into the hydroxy-aluminum montmorillonite to prepare a chewable tablet medicament. By administrating the chewable tablet through a gastrointestinal tract, the effective component of the hydroxy-aluminum montmorillonite chewable tablet can be used for neutralizing a pH value of gastric juice of a patient and further reducing the activity of pepsase, so that the actions of alleviating gastralgia and promoting gastric ulcer healing can be realized; then, the hydroxy-aluminum montmorillonite is discharged outside through a digestive tract, so that the aim of resisting gastric acid is achieved; the hydroxy-aluminum montmorillonite chewable tablet disclosed by the invention is higher in dissolution rate and good in clinical curative effect.

The invention discloses a binding molecule for resisting WNV infection. The binding molecule is a monoclonal antibody aiming at WNV E protein. In-vitro experiments prove that the monoclonal antibody can be specifically combined with WNV E protein, has relatively high affinity activity and can neutralize WNV viruses. On one hand, the research result provides a new method for clinical diagnosis, andon the other hand, a candidate drug is provided for clinical WNV infection resistance.

The invention belongs to the technical field of antibodies, and discloses a monoclonal antibody for recognizing EB (Epstein-Barr) virus gH glycoprotein, and application of the monoclonal antibody. The monoclonal antibody or the antigen binding fragment thereof is subjected to specific binding with the 573th, 625th, 627th and 655th amino acids of the gH protein, wherein the amino acid sequence of the gH protein is as shown in SEQ ID NO. 11. The binding activity of the monoclonal antibody or the antigen binding fragment thereof is superior to the binding activity of other monoclonal antibodies (AMMO1, M3 and 1D8); affinity to the gLgH protein is high; strong neutralizing activity is realized in all epithelial cell infection models; an obvious inhibition effect for cell membrane fusion is achieved; and a way that the monoclonal antibody or the antigen binding fragment thereof is subjected to the specific binding with the 573th, 625th, 627th and 655th amino acids of the gH protein is different from other reported gLgH neutralizing antibody recognition and binding epitopes.

The invention discloses an Fab segment of a human-source human immunodeficiency virus (HIV) antibody, a coded gene thereof and application thereof. The Fab segment of the antibody consists of a variable region (VH) and a constant region subunit CH1 of a heavy chain of the antibody and a light chain of the antibody, wherein the light chain consists of a light chain variable region (VL) and a lightchain constant region (CL); both of the VH and the VL consist of complementary determining regions (CDRs) and framework regions (Framework Region, FRs); the complementary determining region consists of a CDR1, a CDR2 and a CDR3; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the VL are respectively shown as the 27th to the 32nd positions of the sequence 2, the 50th to the 52nd positions of the sequence 2 and the 89th to 98th positions of the sequence 2; and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the VH are respectively shown as the 26th to the 33rd positions of the sequence 3, the 51st to the 58th positions of the sequence 3 and the 97th to 116th positions of the sequence 3. The Fab segment and the coded gene thereof are used for preparing genetic engineering antibodies in different forms and medicaments, vaccines and diagnostic reagents for treating, preventing and diagnosing HIV infection and acquired immune deficiency syndrome.

Provided are a neutralizing antibody against tetanus toxins, and a use thereof. The provided neutralizing antibody against tetanus toxins is capable of specifically binding to tetanus toxins, and thus has strong neutralizing activity and a high affinity, and can be used in a low amount. The provided neutralizing antibody against tetanus toxin can be used for prevention and treatment of tetanus toxin infections and for isolated antibodies of clostridium tetani-mediated diseases or disease conditions, and can also be used to diagnose and/or monitor tetanus toxin infections and isolated antibodies of clostridium tetani infections. Furthermore, the neutralizing antibody against tetanus toxin is free from foreign virus contaminations and can be widely applied to various populations.